GlassScriptPhysician profile
Salem M Sayar
NPI 1346326238
$15,638.49
in general payments reported to CMS, 2019-2025
30 companies · $2,163 in 2025
The $2,163 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $540 · 2021: $1,172 · 2022: $6,868 · 2023: $2,121 · 2024: $1,716 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,512 · Travel and Lodging: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,512.01 |
| Travel and Lodging | $488.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $8,707.04 | 2019-2025 | Carto 3, Qdot Micro Catheter, Qdot Micro |
| Boston Scientific Corporation | $1,343.66 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Farapulse, Emblem Mri S-Icd |
| Medtronic, INC. | $1,213.19 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $849.69 | 2019-2025 | Lifevest |
| Abbott Laboratories | $734.86 | 2019-2025 | Perclose Prostyle, Aveir |
| Medical Device Business Services, INC. | $488.44 | 2023 | Carto 3 |
| Kestra Medical Technology Services, INC. | $345.99 | 2023-2025 | Assure Wcd |
| Philips North America LLC | $333.77 | 2019-2025 | Igt Devices Undivided, (9278) Bridge |
| Pfizer INC. | $279.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $263.84 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $185.01 | 2019-2025 | Camzyos |
| Cardiva Medical, INC. | $182.64 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Biotronik INC. | $116.45 | 2025 | Selectra |
| Cordis US Corp. | $97.36 | 2025 | Mynx Control Venous |
| Sanofi-Aventis U.S. LLC | $94.22 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $64.42 | 2019-2020 | |
| Abiomed | $50.91 | 2025 | |
| Medtronic Vascular, INC. | $49.13 | 2020 | |
| Impulse Dynamics (USA) INC. | $43.46 | 2023 | Optimizer |
| Angiodynamics, INC. | $29.45 | 2021 | |
| Elutia, INC. | $28.36 | 2019 | |
| Atricure, INC. | $18.27 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Portola Pharmaceuticals, LLC | $18.01 | 2019 | |
| Amarin Pharma, INC. | $15.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.74 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.37 | 2020 | |
| Davol INC. | $15.30 | 2019 | |
| Astellas Pharma US INC | $14.14 | 2023 | Lexiscan |
| Chiesi USA, INC. | $13.79 | 2025 | Cleviprex, Kengreal |
| Janssen Scientific Affairs, LLC | $10.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salem Sayar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.